Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      BIOLASE Reports Strong Sequential Revenue Growth In Third Quarter 2020

      Reopening of Dental Practices Drives Sequential Revenue Growth

      Clinically Proven Product Portfolio Reduces Potential Risk of Infectious Pathogens; Creates Significant Growth Opportunities as Dental Professionals Seek Safer Technologies to Treat Patients

      BIOLASE Logo (PRNewsfoto/BIOLASE, Inc.)

      News provided by

      BIOLASE, Inc.

      Nov 12, 2020, 16:05 ET

      Share this article

      Share this article


      FOOTHILL RANCH, Calif., Nov. 12, 2020 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced its financial results for the third quarter ended September 30, 2020.

      Third Quarter 2020 Financial Highlights:

      • U.S. laser revenue increased 16% year over year
      • U.S. consumables and other revenue increased 25% year over year
      • New customers represented over 90% of U.S. laser sales in the quarter
      • Total revenue more than doubled sequentially, while down 24% year over year
      • Operating expenses decreased 24% year over year
      • Significantly strengthened balance sheet with an $18.0 million equity raise

      "Our significantly improved third quarter revenue was driven by several factors, including 95% of dental offices having reopened in the United States, dental procedure levels having reached 70-80% of their pre-Covid-19 levels, and the fact that our product portfolio reduces the risk of infectious pathogens," said Todd Norbe, President and Chief Executive Officer. "Our Epic Hygiene dental laser meets the Centers for Disease Control and Prevention (CDC) guidelines to minimize the risk of COVID-19, while our all-tissue Waterlase dental lasers create 98% less aerosol than traditional dental handpieces, meeting the American Dental Association's recommendation of reduced aerosol production to limit the spread of infectious pathogens, such as COVID-19. These unique attributes meet the rising needs of both dentists and patients as they look for solutions that allow them to provide and receive dental treatment in the safest way possible."  

      2020 Third Quarter Financial Results

      Net revenue for the third quarter of 2020 was $6.5 million, an increase of 124% sequentially from second quarter revenue of $2.9 million, and a decrease of 24% compared to net revenue of $8.6 million for the third quarter of 2019. U.S. laser revenue was $2.7 million in the third quarter of 2020, up 16% when compared to U.S. laser revenue of $2.3 million for the third quarter of 2019. This increase is due to higher average selling prices in the third quarter of 2020 than in 2019. U.S. consumables and other revenue for the third quarter of 2020, which consists of revenue from consumable products such as disposable tips, increased 25% compared to the third quarter of 2019. Outside the U.S., laser revenue declined 64% to $1.0 million for the third quarter of 2020 compared to $2.8 million for the third quarter of 2019.

      Gross margin for the third quarter of 2020 was 35%, compared to 34% for the third quarter of 2019. The higher gross margin reflects higher average U.S. selling prices of our lasers and a higher percentage of U.S. sales, partially offset by a decline in revenues relative to our fixed costs. Total operating expenses were $5.9 million for the third quarter of 2020 compared to $7.9 million for the third quarter of 2019, a decrease of approximately 24%. Operating loss for the third quarter of 2020 was $3.7 million, compared to an operating loss of $4.9 million in the third quarter of 2019, a decrease of 25% year over year. Net income for the third quarter of 2020 was $12,000 and less than $0.01 per share before a deemed dividend on preferred stock of $17.4 million, compared to a net loss of $5.5 million, or $0.25 per share, for the third quarter of 2019. Net loss after the deemed dividend was $17.4 million or $0.21 per share for the three months ended September 30, 2020.

      Cash, cash equivalents, and restricted cash totaled $19.2 million as of September 30, 2020, and included proceeds from the rights offering completed in July.

      Use of Non-GAAP Measures

      The Reconciliation of GAAP Net Loss to Adjusted EBITDA at the end of this news release provides the details of the Company's non-GAAP disclosures and the reconciliation of GAAP net loss and net loss per share to the Company's Adjusted EBITDA and Adjusted EBITDA per share.

      Adjusted EBITDA loss for the third quarter of 2020 was $2.5 million, or $0.03 per share, compared with Adjusted EBITDA loss of $2.7 million, or $0.12 per share, for the third quarter of 2019.

      Conference Call Information

      BIOLASE, Inc. will host a conference call today at 4:30 p.m. Eastern Time to discuss its operating results for the third quarter ended September 30, 2020, and to answer questions. For both "listen-only" participants and those participants who wish to take part in the question-and-answer portion of the call, the dial-in number in the U.S./Canada is 800-367-2403. For international participants outside the U.S./Canada, the dial-in number is 334-777-6978. For all callers, refer to the Conference ID 9286776. To access the live webcast, visit the Investor Relations section of the BIOLASE website at www.biolase.com and see "Investor Events".

      An audio archive of the webcast will be available for 30 days on the Investor Relations section of the BIOLASE website.

      About BIOLASE

      BIOLASE is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine.  BIOLASE's products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE's proprietary laser products incorporate approximately patented 259 and 41 patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. BIOLASE's innovative products provide cutting-edge technology at competitive prices to deliver superior results for dentists and patients. BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including the treatment of periodontitis, and a full line of dental imaging equipment. BIOLASE has sold over 41,500 laser systems to date in over 80 countries around the world. Laser products under development address BIOLASE's core dental market and other adjacent medical and consumer applications.

      For updates and information on Waterlase iPlus®, Waterlase Express™, and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Instagram at www.instagram.com/waterlase_laserdentistry, and LinkedIn at www.linkedin.com/company/biolase.

      BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.

      Cautionary Statement Regarding Forward-Looking Statements

      This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties, including statements, predictions, or expectations regarding BIOLASE's revenue during the third quarter of 2020. Forward-looking statements can be identified through the use of words such as may," "might," "will," "intend," "should," "could," "can," "would," "continue," "expect," "believe," "anticipate," "estimate," "predict," "outlook," "potential," "plan," "seek," and similar expressions and variations or the negatives of these terms or other comparable terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE's current expectations depending upon a number of factors. These factors include, among others, the coronavirus (COVID-19) and the effects of the outbreak and actions taken in connection therewith,  adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that are described in the "Risk Factors" section of BIOLASE's annual report filed on Form 10-K filed with the Securities and Exchange Commission. Except as required by law, BIOLASE does not undertake any responsibility to revise or update any forward-looking statements.

      Tables to Follow

      BIOLASE, INC.

      CONSOLIDATED STATEMENTS OF OPERATIONS

      (Unaudited)

      (In thousands, except per share data)




      Three Months Ended



      Nine Months Ended



      September 30,



      September 30,



      2020



      2019



      2020



      2019

      Net revenue


      $


      6,539



      $


      8,646



      $


      14,260



      $


      27,617

      Cost of revenue




      4,265





      5,677





      9,692





      17,746

      Gross profit




      2,274





      2,969





      4,568





      9,871

      Operating expenses:




















      Sales and marketing




      2,678





      3,515





      7,475





      10,665

      General and administrative




      2,300





      3,210





      7,446





      8,114

      Engineering and development




      963





      1,126





      2,644





      3,665

      Total operating expenses




      5,941





      7,851





      17,565





      22,444

      Loss from operations




      (3,667)





      (4,882)





      (12,997)





      (12,573)

      (Gain) loss on foreign currency transactions




      (53)





      19





      68





      68

      Interest expense, net




      568





      551





      1,782





      1,559

      Other (income) expense, net




      (4,209)





      —





      (4,209)





      —

      Non-operating loss




      (3,694)





      570





      (2,359)





      1,627

      Income (loss) before tax provision




      27





      (5,452)





      (10,638)





      (14,200)

      Income tax provision




      15





      26





      49





      68

      Net income (loss)


      $


      12



      $


      (5,478)



      $


      (10,687)



      $


      (14,268)





















      Net income (loss)


      $


      12



      $


      (5,478)



      $


      (10,687)



      $


      (14,268)

      Deemed dividend on convertible preferred stock




      (17,378)





      —





      (17,378)





      —

      Net loss per share attributable to common stockholders:


      $


      (17,366)



      $


      (5,478)



      $


      (28,065)



      $


      (14,268)





















      Basic


      $


      (0.21)



      $


      (0.25)



      $


      (0.56)



      $


      (0.66)

      Diluted


      $


      (0.21)



      $


      (0.25)



      $


      (0.56)



      $


      (0.66)

      Shares used in the calculation of net loss per share:




















      Basic




      81,341





      21,898





      50,366





      21,545

      Diluted




      81,341





      21,898





      50,366





      21,545

      BIOLASE, INC.


      CONSOLIDATED BALANCE SHEETS


      (In thousands, except per share data)















      September 30,



      December 31,




      2020



      2019




      (Unaudited)



      (Audited)


      ASSETS











      Current assets:











      Cash and cash equivalents


      $


      18,847



      $


      5,789


      Restricted cash




      312





      312


      Accounts receivable, less allowance of $3,837 and $2,531 in 2020 and 2019, respectively




      3,393





      8,760


      Inventory




      12,592





      10,995


      Prepaid expenses and other current assets




      903





      1,163


      Total current assets




      36,047





      27,019


      Property, plant and equipment, net




      742





      1,193


      Goodwill




      2,926





      2,926


      Right of use asset




      2,061





      276


      Other assets




      220





      433


      Total assets


      $


      41,996



      $


      31,847













      LIABILITIES, REDEEMABLE PREFERRED STOCK AND

      STOCKHOLDERS' EQUITY









      Current liabilities:











      Accounts payable


      $


      2,592



      $


      5,332


      Accrued liabilities




      4,279





      4,744


      Deferred revenue, current portion




      1,616





      2,237


      Term loan (net of discount)




      12,946





      13,466


      Total current liabilities




      21,433





      25,779


      Deferred revenue




      412





      358


      Warranty accrual




      204





      245


      Other liabilities




      1,097





      1,119


      Non current lease liability




      1,859





      4


      Non current term loans




      3,140





      —


      Total liabilities




      28,145





      27,505


      Redeemable preferred stock:











      Series E Preferred stock, par value $0.001 per share


      $


      —



      $


      3,965


      Total redeemable preferred stock




      —





      3,965


      Stockholders' equity:











      Series F Preferred Stock, par value $0.001 per share




      141





      —


      Common stock, par value $0.001 per share




      93





      31


      Additional paid-in capital




      259,385





      235,594


      Accumulated other comprehensive loss




      (534)





      (701)


      Accumulated deficit




      (245,234)





      (234,547)


      Total stockholders' equity




      13,851





      377


      Total liabilities, redeemable preferred stock and stockholders' equity


      $


      41,996



      $


      31,847


      BIOLASE, INC.

      CONSOLIDATED STATEMENTS OF CASH FLOWS

      (Unaudited, in thousands)











      Nine Months Ended



      September 30,



      2020



      2019

      Cash Flows from Operating Activities:








      Net loss


      $

      (10,687)



      $

      (14,268)

      Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:








      Depreciation and amortization



      527




      754

      Provision for bad debts



      1,263




      1,243

      Provision for sales returns



      87




      —

      Amortization of discounts on lines of credit



      123




      103

      Amortization of debt issuance costs



      240




      130

      Change in fair value of warrants



      (5,850)




      —

      Issuance costs for common stock warrants



      1,640




      —

      Earned interest income



      —




      2

      Stock-based compensation



      2,367




      1,974

      Deferred income taxes



      —




      (6)

      Changes in operating assets and liabilities:








      Accounts receivable



      4,017




      1,393

      Inventory



      (1,597)




      711

      Prepaid expenses and other current assets



      430




      1,011

      Accounts payable and accrued liabilities



      (3,445)




      (1,157)

      Deferred revenue



      (562)




      36

      Net cash and cash equivalents used in operating activities



      (11,447)




      (8,074)

      Cash Flows from Investing Activities:








      Purchases of property, plant, and equipment



      (78)




      (138)

      Net cash and cash equivalents used in investing activities



      (78)




      (138)

      Cash Flows from Financing Activities:








      Proceeds from the issuance of common stock



      6,912




      —

      Proceeds from the issuance of Series F Convertible Preferred Stock



      2,700




      —

      Proceeds from the issuance of July 2020 Warrants



      15,300




      —

      Payments of equity offering costs



      (1,281)




      (50)

      Payments of warrant issuance costs



      (1,640)




      —

      Borrowings on other long-term loans



      3,140




      —

      Borrowings under term loan



      —




      2,500

      Principal payment on term loan



      (700)




      —

      Borrowings on credit facility



      3,000




      —

      Repayment of credit facility



      (3,000)




      —

      Proceeds from the exercise of common stock warrants



      46




      —

      Payment of debt issuance costs



      (75)




      (38)

      Proceeds from exercise of stock options



      —




      4

      Net cash and cash equivalents provided by financing activities



      24,402




      2,416

      Effect of exchange rate changes



      181




      (157)

      Decrease in cash, cash equivalents and restricted cash



      13,058




      (5,953)

      Cash, cash equivalents and restricted cash, beginning of period



      6,101




      8,356

      Cash, cash equivalents and restricted cash, end of period


      $

      19,159



      $

      2,403

      Supplemental cash flow disclosure:








      Cash paid for interest


      $

      1,438



      $

      1,315

      Cash paid for income taxes


      $

      21



      $

      19

      Cash paid for operating leases


      $

      417



      $

      414

      Non-accrual for accrual for equity offering costs


      $

      —



      $

      191

      Non-cash accrual for capital expenditures


      $

      —



      $

      4

      Non-cash settlement of performance award liability


      $

      151



      $

      —

      Non-cash right-of-use assets obtained in exchange for lease obligation


      $

      2,037



      $

      824

      Deemed dividend on preferred stock


      $

      17,378



      $

      —

      Warrants issued in connection with debt instruments


      $

      67



      $

      209

      Non-GAAP Disclosure

      In addition to the financial information prepared in conformity with generally accepted accounting principles in the U.S. ("GAAP"), this press release includes certain historical non-GAAP financial information. Management believes that these non-GAAP financial measures assist investors in making comparisons of period-to-period operating results and that, in some respects, these non-GAAP financial measures are more indicative of the Company's ongoing core operating performance than their GAAP equivalents. In 2019, the Company revised its non-GAAP financial measures to include the change in allowance for doubtful accounts in an effort to better align its Adjusted EBITDA with its loan covenants and how management evaluates business performance.

      Adjusted EBITDA is defined as net loss before interest, taxes, depreciation and amortization, stock-based compensation, change in fair value of patent litigation settlement liability, and allowance for doubtful accounts. Management uses Adjusted EBITDA in its evaluation of the Company's core results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Further, the non-GAAP financial measures presented by the Company may be different from similarly named non-GAAP financial measures used by other companies.

      BIOLASE, INC.

      Reconciliation of GAAP Net Loss to Adjusted EBITDA

      (Unaudited)

      (In thousands, except per share data)














      Three Months Ended



      Nine Months Ended


      September 30



      September 30


      2020



      2019



      2020



      2019

      GAAP net loss attributable to common stockholders

      $


      (17,366)



      $


      (5,478)



      $


      (28,065)



      $


      (14,268)

      Deemed dividend on convertible preferred stock



      17,378





      —





      17,378





      —

      GAAP net income (loss)

      $


      12



      $


      (5,478)



      $


      (10,687)



      $


      (14,268)

      Adjustments:



















      Interest expense, net



      568





      551





      1,782





      1,559

      Income tax provision



      15





      26





      49





      68

      Depreciation and amortization



      46





      268





      527





      754

      Change in allowance for doubtful accounts



      256





      1,131





      1,263





      1,243

      Stock-based compensation



      847





      770





      2,367





      1,974

      Other (income) expense, net



      (4,209)





      —





      (4,209)





      —

      Adjusted EBITDA

      $


      (2,465)



      $


      (2,732)



      $


      (8,908)



      $


      (8,670)




















      GAAP net loss attributable to common stockholders

         per share, basic and diluted

      $


      (0.21)



      $


      (0.25)



      $


      (0.56)



      $


      (0.66)

      Deemed dividend on convertible preferred stock



      0.21





      —





      0.35





      —

      GAAP net income (loss) per share, basic and diluted

      $


      0.00



      $


      (0.25)



      $


      (0.21)



      $


      (0.66)

      Adjustments:



















      Interest expense, net



      0.01





      0.03





      0.04





      0.07

      Income tax provision



      —





      —





      —





      —

      Depreciation and amortization



      —





      0.01





      0.01





      0.03

      Change in allowance for doubtful accounts



      —





      0.05





      0.02





      0.06

      Stock-based compensation



      0.01





      0.04





      0.04





      0.09

      Other (income) expense, net



      (0.05)





      —





      (0.08)





      —

      Adjusted EBITDA per share, basic and diluted

      $


      (0.03)



      $


      (0.12)



      $


      (0.18)



      $


      (0.41)

      SOURCE BIOLASE, Inc.

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.